Choose a language and wait for the translated text.
Lupin has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg.
The U.S. FDA has approved Lupinβs Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labelling.
The post Lupin receives USFDA approval for Pitolisant Tablets appeared first on Express Pharma.
Lupin receives USFDA approval for Pitolisant Tablets | PharmaVoice
